Influence of <i>TP53</i> Comutation on the Tumor Immune Microenvironment and Clinical Outcomes With Immune Checkpoint Inhibitors in <i>STK11</i>-Mutant Non–Small-Cell Lung Cancer
Abdul Rafeh Naqash(Oklahoma City University), Hirva Mamdani(Wayne State University), Luis E. Raez(Florida International University), Asaf Maoz(Dana-Farber Cancer Institute), Biagio Ricciuti(Harvard University), Khalil Choucair(The Barbara Ann Karmanos Cancer Institute), Stephen V. Liu(Georgetown University), Charalampos S. Floudas(National Cancer Institute), Elio Adib(Dana-Farber Brigham Cancer Center), Gilberto Lopes(University of Miami), Jorge J. Nieva(University of Southern California), Yasmine Baca(Caris Life Sciences (United States)), C. Patrick(Pennsylvania State University), Amin H. Nassar(Brigham and Women's Hospital), Joanne Xiu(Caris Life Sciences (United States)), Balázs Halmos(Montefiore Medical Center), Naoko Takebe(National Cancer Institute), Joao V. Alessi(Hospital Sírio-Libanês), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Etan Aber(National Cancer Institute), David J. Kwiatkowski(Brigham and Women's Hospital), J. Judd(Fox Chase Cancer Center), Chul Kim(Georgetown University), Hossein Borghaei(Fox Chase Cancer Center)
Cited by 5
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Sotorasib for Lung Cancers with <i>KRAS</i> p.G12C Mutation
|New England Journal of Medicine|2021|1.8k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k